文献速递特殊人群用药

奥卡西平及其活性代谢物群体药代动力学建模指导肥胖儿童给药

Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity.
PubMed 文献 · Clin Pharmacokinet · 2025-11-17

去脂体重衍生的药代动力学体重(PKWT)是唯一显著协变量。模拟显示当前儿童给药方案在肥胖与非肥胖儿童中产生相似的MHD暴露。

要点

  • 去脂体重衍生的PKWT是影响OXZ和MHD药代动力学的唯一显著协变量。
  • 模拟显示当前OXZ儿童给药方案在肥胖与非肥胖儿童中MHD暴露相当。
  • 现有儿童剂量方案可适用于肥胖儿童,无需根据肥胖状态调整。

核心结论

  • 基于模型的分析证实,当前奥卡西平儿童给药方案适用于一般儿童,无论其肥胖状态如何。

研究设计与样本

  • 共获得425个血浆浓度(OXZ n=212,MHD n=213),采用LC-MS/MS测定,用NONMEM 7.4进行非线性混合效应建模。

主要发现

  • 一房室母体-代谢物联合模型(线性输入输出及OXZ与MHD双向转化)最佳表征药代动力学。
  • 体尺是唯一影响药代动力学的协变量,去脂体重衍生的PKWT以异速生长方式最佳表征其效应。
  • 模拟显示当前OXZ给药方案在≥2岁肥胖与非肥胖儿童中产生可比的MHD暴露。

关键数值与推荐

  • 肥胖定义为≥2岁且BMI≥第95百分位。
  • 当前儿童给药方案按年龄和体重分层,适用于肥胖儿童无需调整。

临床怎么用

  • 临床可为肥胖儿童使用与同年龄/体重非肥胖儿童相同的奥卡西平标准剂量方案。
  • 无需因肥胖状态进行额外剂量调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oxcarbazepine (OXZ) is an antiepileptic drug whose pharmacological effect is primarily mediated by its active metabolite, 10-monohydroxy derivative (MHD). OXZ is approved for use in adults and children older than 2 years with an age- and body weight-tiered dosing recommendation, but dosing guidance for children with obesity is lacking. OBJECTIVE: This work aimed to assess the dosing requirements of OXZ in children with obesity to support label extension. METHODS: Two multicenter studies (NCT01431326 and NCT02993861) were conducted in patients receiving standard-of-care OXZ therapy. Participants ≥ 2 years of age with a body mass index ≥ 95th percentile were classified as obese. Plasma concentrations were measured by a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) assay. Nonlinear mixed effects modeling was performed using NONMEM 7.4 to characterize the population pharmacokinetics of OXZ and MHD simultaneously. Simulations were performed to compare MHD systemic exposure in children ≥ 2 years of age with and without obesity. RESULTS: One hundred study participants with a median (range) age of 9 years (44 days-20.90 years) contributed 425 plasma concentrations of OXZ (n = 212) and MHD (n = 213). Fifty-two percent of the participants had obesity. A one-compartment joint parent-metabolite model with linear input-output and bi-directional transformation between OXZ and MHD best characterized the pharmacokinetics. Body size was the only covariate affecting pharmacokinetics, and a fat-free mass-based metric termed pharmacokinetic weight (PKWT) best characterized that effect allometrically. Simulation results revealed that the current dosing regimen of OXZ can produce comparable exposure of MHD in children ≥ 2 years of age with and without obesity. CONCLUSION: A model-informed analysis confirms that the current pediatric dosing regimen of OXZ applies to children in general, regardless of their obesity status.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Sinha J, Zimmerman K, Balevic SJ, et al. Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity. Clin Pharmacokinet. 2025. PMID: 41247430. doi:10.1007/s40262-025-01579-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。